NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
4.910
+0.060 (1.24%)
At close: Nov 13, 2026, 4:00 PM EST
4.940
+0.030 (0.61%)
After-hours: Nov 13, 2026, 7:30 PM EST
NTHI Revenue
NeOnc Technologies Holdings had revenue of $39.99K in the twelve months ending September 30, 2026, up 99.95% year-over-year. In the year 2025, NeOnc Technologies Holdings had annual revenue of $39.99K, down -51.82%. That makes NeOnc Technologies Holdings the 46,672nd largest company in the world by revenue and 6,986th in the United States.
Revenue (ttm)
$39.99K
Revenue Growth
+99.95%
P/S Ratio
3,409.75
Revenue / Employee
$7,998
Employees
5
Market Cap
136.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.99K | -43.01K | -51.82% |
| Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
| Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
| Dec 31, 2022 | 20.00K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Cellectis | 63.82M |
| Voyager Therapeutics | 25.11M |
| Equillium | 4.39M |
| NRx Pharmaceuticals | 3.39M |
| Molecular Partners AG | 856.30K |
| Outlook Therapeutics | -1.16M |
NTHI News
- 21 hours ago - NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach - GlobeNewsWire
- 1 day ago - NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial - GlobeNewsWire
- 1 day ago - NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations - GlobeNewsWire
- 2 days ago - FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track - GlobeNewsWire
- 2 days ago - NeOnc granted Type B End-of-Phase meeting by FDA for intranasal NEO100 - TheFly
- 2 days ago - NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 - GlobeNewsWire
- 4 days ago - NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues - GlobeNewsWire
- 8 days ago - NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - GlobeNewsWire